<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03714620</url>
  </required_header>
  <id_info>
    <org_study_id>211328</org_study_id>
    <nct_id>NCT03714620</nct_id>
  </id_info>
  <brief_title>Sub-dissociative Dose Ketamine Dosing Study</brief_title>
  <official_title>A Randomized, Controlled Trial of Intravenous Sub-dissociative Ketamine at Two Doses for Analgesia in the Emergency Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loyola University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loyola University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Goal is to determine if in adults presenting to the Emergency Department (ED) with moderate
      to severe acute pain, Ketamine administered at 0.15 mg/kg will provide similar pain relief to
      Ketamine administered at 0.3 mg/kg, with fewer adverse effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study investigators will enroll participants who present to the Emergency Department (ED)
      with moderate to severe acute pain, and require intravenous pain medication. Participants
      will be double-blinded and randomized to one of the two treatment groups.

      Investigators aim to determine if ketamine 0.15 mg/kg IVPB is non-inferior to ketamine 0.3
      mg/kg IVBP for the treatment of acute moderate to severe pain in the Emergency Department
      (ED). Study investigators hypothesize that in adults presenting to the ED with moderate to
      severe acute pain, SDK administered at 0.15 mg/kg will provide similar pain relief to SDK at
      0.3 mg/kg, with reduced adverse effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 15, 2018</start_date>
  <completion_date type="Actual">September 17, 2019</completion_date>
  <primary_completion_date type="Actual">September 17, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>The sequence will be generated using randomization permuted blocks of 2 and 4 patients, with the allocated dose revealed using an online randomization module within the REDCap data management system.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>All study investigators, patients and clinicians except the clinical pharmacist will be blinded to the study treatment allocation. Treatment will be prepared and blinded by the ED clinical pharmacist.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in pain score from baseline to 30 minutes post initiation of drug administration</measure>
    <time_frame>30 minutes</time_frame>
    <description>Reduction in pain score from time 0 to time 30 min</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in pain score from baseline to 15 minutes</measure>
    <time_frame>15 minutes</time_frame>
    <description>Reduction in pain score from time 0 to time 15 min post initiation of drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in pain score from baseline to 60 minutes</measure>
    <time_frame>60 minutes</time_frame>
    <description>Reduction in pain score from time 0 to time 60 min post initiation of drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for rescue medications at 30 minutes</measure>
    <time_frame>30 minutes</time_frame>
    <description>Patient request for additional pain medications at 30 minutes post initiation of drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for rescue medications at 60 minutes</measure>
    <time_frame>60 minutes</time_frame>
    <description>Patient request for additional pain medications at 60 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in heart rate</measure>
    <time_frame>60 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic/diastolic blood pressure</measure>
    <time_frame>60 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in oxygen saturation</measure>
    <time_frame>60 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects at 30 min</measure>
    <time_frame>30 minutes</time_frame>
    <description>Patients were asked if they had any adverse effects at 30 minutes including nausea, dizziness, headache, hallucinations, etc.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>0.15 mg/kg IV Ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.3 mg/kg IV Ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine 0.15 mg/kg vs. 0.3 mg/kg IVPB over 15 minutes</description>
    <arm_group_label>0.15 mg/kg IV Ketamine</arm_group_label>
    <arm_group_label>0.3 mg/kg IV Ketamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults ages 18-59

          -  Weight 45 - 115 kg

          -  Acute abdominal, flank, back, musculoskeletal pain, or a headache

          -  Onset of pain within 7 days

          -  Pain score of 5 or more

          -  Requiring intravenous analgesia

          -  Hasn't been enrolled in this study previously

        Exclusion Criteria:

          -  Pregnancy

          -  Breast-feeding

          -  Altered mental status rendering the patient unable to consent to the study

          -  Allergy to ketamine

          -  Unstable vital signs (systolic blood pressure &lt;90 or &gt;180 mm Hg, pulse rate &lt;50 or
             &gt;150 beats/minute, and respiration rate &lt;10 or &gt;30 breaths/minute)

          -  History of acute head or eye injury, seizure, intracranial hypertension

          -  Chronic pain

          -  Renal or hepatic insufficiency

          -  Known alcohol or drug use disorder

          -  Currently under influence of alcohol/opiates

          -  Acute psychiatric illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 17, 2018</study_first_submitted>
  <study_first_submitted_qc>October 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2018</study_first_posted>
  <last_update_submitted>October 22, 2019</last_update_submitted>
  <last_update_submitted_qc>October 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loyola University</investigator_affiliation>
    <investigator_full_name>Shannon Lovett</investigator_full_name>
    <investigator_title>Associate Professor of Department of Emergency Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

